Accolade (ACCD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live ...

Core Insights - Celeste Health Solutions is a new company focused on integrating data insights, technology, and personalized health management to simplify healthcare access for employees and reduce burdens for employers [1][7] - The company aims to streamline the healthcare experience by offering a comprehensive product that includes health navigation, personalized engagement, virtual care, and benefits support [2][7] Company Overview - Celeste was launched in 2024 and is designed to address significant challenges in healthcare for employers and their workforce [7] - The company integrates various health solutions into a single platform, allowing members to access all benefits through an intuitive app and communicate directly with health assistants [7] Member Engagement and Care Coordination - Celeste creates personalized care plans for members, identifying and ranking interventions while coordinating care [2][4] - The company emphasizes proactive member engagement and coordinated communication among clinical care teams to enhance health outcomes [4][6] Innovations Hub - Celeste's Innovations Hub aims to alleviate administrative burdens for employers by providing a curated portfolio of point solutions, streamlining contracting and billing processes [3][4] - The company offers deep analysis and actionable insights to tackle healthcare challenges faced by employers [3] Partnership with Accolade - Celeste collaborates with Accolade to enhance personalized healthcare delivery, integrating virtual care options and expert medical opinions [5] - This partnership aims to proactively engage employees and their families, supporting them in achieving better health outcomes [5] Proactive Health Management - Unlike traditional health plans that rely on claims history, Celeste adopts a proactive approach using demographic trends and whole-person health insights to tailor care [6] - The goal is to prevent or slow the progression of various health conditions by matching members with suitable solutions [6]

Company Overview - Accolade, Inc. is a Personalized Healthcare company that aims to provide exceptional healthcare experiences to millions of people and their families, enabling them to live healthier lives [2] - The company's solutions include virtual primary care, mental health services, expert medical opinions, and care navigation, all built on a platform that focuses on predictive engagement and proactive care [2] - Accolade consistently achieves consumer satisfaction ratings exceeding 90% [2] Upcoming Events - Accolade will present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase in Boston on August 14, 2024, at 12:00 pm ET [1] - A webcast of the presentation will be available on the company's investor relations website, with a replay accessible for 90 days [1]

Core Viewpoint - Accolade (ACCD) has experienced significant selling pressure, resulting in a 47% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Stock Performance and Indicators - ACCD's stock is currently in oversold territory, with a Relative Strength Index (RSI) reading of 19.38, suggesting that the heavy selling may be exhausting itself [2][4]. - A stock is generally considered oversold when its RSI falls below 30, indicating a potential price reversal [2]. Group 2: Earnings Estimates and Analyst Sentiment - Over the last 30 days, the consensus earnings per share (EPS) estimate for ACCD has increased by 5.1%, reflecting a strong agreement among analysts regarding improved earnings [4]. - ACCD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [4].

Group 1 - Accolade (ACCD) has experienced a significant decline of 47% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for ACCD is at 18.75, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a rebound [2][4] - There is a strong consensus among Wall Street analysts that ACCD will report better earnings than previously predicted, with a 5.1% increase in the consensus EPS estimate over the last 30 days [4] Group 2 - ACCD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [4]

Core Viewpoint - Accolade, Inc. is under investigation for potential claims following a significant quarterly loss and a sharp decline in stock price after its earnings report [2][5]. Investigation Details - On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share, leading to a more than 27% drop in stock price during after-hours trading [2]. Next Steps - Investors who have information related to the investigation or who purchased Accolade securities are encouraged to assist by visiting the firm's website or contacting the firm's representatives [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful in recovering funds for investors [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has successfully recovered hundreds of millions of dollars for investors [5].

ipopba Elevator Pitch I have a Hold investment rating for Accolade, Inc. (NASDAQ:ACCD) stock. My prior April 5, 2024 write-up drew attention to Accolade's latest corporate developments like the addition of new partners. The current update reviews ACCD's Q1 FY 2025 (YE February 28, 2025) financial performance and evaluates the company's financial prospects. Accolade's Q1 results benefited from a favorable timing difference, but its updated full-year guidance was mixed. ACCD lowered its FY 2025 top line guida ...

Accolade, Inc. (NASDAQ:ACCD) Q1 2025 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Todd Friedman - SVP of IR Rajeev Singh - CEO Steve Barnes - CFO Conference Call Participants Richard Close - Canaccord Genuity Craig Hettenbach - Morgan Stanley Michael Cherny - Leerink Partners Jeff Garro - Stephens Inc. Ryan Daniels - William Blair Jailendra Singh - Truist Securities Jessica Tassan - Piper Sandler Ryan MacDonald - Needham & Company Stephanie Davis - Barclays Stan Berenshteyn ...

Group 1 - Accolade reported a quarterly loss of $0.35 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and improved from a loss of $0.52 per share a year ago, indicating an earnings surprise of 27.08% [1] - The company generated revenues of $110.47 million for the quarter ended May 2024, exceeding the Zacks Consensus Estimate by 5.20%, and up from $93.23 million in the same quarter last year [1] - Accolade has surpassed consensus EPS estimates and revenue estimates four times over the last four quarters [1] Group 2 - Accolade shares have declined approximately 49% since the beginning of the year, contrasting with the S&P 500's gain of 14.9% [2] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [2] - The estimate revisions trend for Accolade is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [3] Group 3 - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $112.94 million, and for the current fiscal year, it is -$1.23 on revenues of $490.58 million [4] - The Technology Services industry, to which Accolade belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook [4]